Q3161165 (Q3161165): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): Alzheimer’s disease (AD) is the most common form of dementia, affecting 24 million people in the world. Current approaches to AD treatment have not been successful because they have focused on the time of onset of symptoms, when the disease is already irreversible. Brain damage in AD begins 20 years before dementia is evident, indicating that the focus should focus on early preventive strategies, so it is of utmost importance to understand the f...) |
||||||||||||||
| Property / summary | |||||||||||||||
Alzheimer’s disease (AD) is the most common form of dementia, affecting 24 million people in the world. Current approaches to AD treatment have not been successful because they have focused on the time of onset of symptoms, when the disease is already irreversible. Brain damage in AD begins 20 years before dementia is evident, indicating that the focus should focus on early preventive strategies, so it is of utmost importance to understand the factors that lead to the development of AD in its asymptomatic stage. In recent years AD has been linked to risk factors for atherosclerosis. In fact, similar to AD, atherosclerosis begins many years before symptoms appear. Current studies linking the two pathologies are based on cross-sectional studies in symptomatic stages. To understand the interrelationship between the two diseases, we propose to carry out a study that evaluates the trajectories (initiation and progression) of AD and atherosclerosis in their asymptomatic stages. To do this, we will take advantage of a large cohort of asymptomatic middle-aged participants in whom the degree of subclinical atherosclerosis has already been characterised in detail, the study of progression of early subclinical atherosclerosis (PESA). We propose to include in this study PESA different brain analyses to detect subtle cognitive decline and brain changes typical of preclinical AD by advanced image, and correlate them with the degree and progression of the presence of subclinical atherosclerosis. The demonstration of related paths of AD and atherosclerosis in their asymptomatic stages will open up the possibility for future intervention strategies to curb the global epidemics of both diseases. (English) | |||||||||||||||
| Property / summary: Alzheimer’s disease (AD) is the most common form of dementia, affecting 24 million people in the world. Current approaches to AD treatment have not been successful because they have focused on the time of onset of symptoms, when the disease is already irreversible. Brain damage in AD begins 20 years before dementia is evident, indicating that the focus should focus on early preventive strategies, so it is of utmost importance to understand the factors that lead to the development of AD in its asymptomatic stage. In recent years AD has been linked to risk factors for atherosclerosis. In fact, similar to AD, atherosclerosis begins many years before symptoms appear. Current studies linking the two pathologies are based on cross-sectional studies in symptomatic stages. To understand the interrelationship between the two diseases, we propose to carry out a study that evaluates the trajectories (initiation and progression) of AD and atherosclerosis in their asymptomatic stages. To do this, we will take advantage of a large cohort of asymptomatic middle-aged participants in whom the degree of subclinical atherosclerosis has already been characterised in detail, the study of progression of early subclinical atherosclerosis (PESA). We propose to include in this study PESA different brain analyses to detect subtle cognitive decline and brain changes typical of preclinical AD by advanced image, and correlate them with the degree and progression of the presence of subclinical atherosclerosis. The demonstration of related paths of AD and atherosclerosis in their asymptomatic stages will open up the possibility for future intervention strategies to curb the global epidemics of both diseases. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Alzheimer’s disease (AD) is the most common form of dementia, affecting 24 million people in the world. Current approaches to AD treatment have not been successful because they have focused on the time of onset of symptoms, when the disease is already irreversible. Brain damage in AD begins 20 years before dementia is evident, indicating that the focus should focus on early preventive strategies, so it is of utmost importance to understand the factors that lead to the development of AD in its asymptomatic stage. In recent years AD has been linked to risk factors for atherosclerosis. In fact, similar to AD, atherosclerosis begins many years before symptoms appear. Current studies linking the two pathologies are based on cross-sectional studies in symptomatic stages. To understand the interrelationship between the two diseases, we propose to carry out a study that evaluates the trajectories (initiation and progression) of AD and atherosclerosis in their asymptomatic stages. To do this, we will take advantage of a large cohort of asymptomatic middle-aged participants in whom the degree of subclinical atherosclerosis has already been characterised in detail, the study of progression of early subclinical atherosclerosis (PESA). We propose to include in this study PESA different brain analyses to detect subtle cognitive decline and brain changes typical of preclinical AD by advanced image, and correlate them with the degree and progression of the presence of subclinical atherosclerosis. The demonstration of related paths of AD and atherosclerosis in their asymptomatic stages will open up the possibility for future intervention strategies to curb the global epidemics of both diseases. (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 16:44, 12 October 2021
Project Q3161165 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3161165 in Spain |
Statements
48,500.0 Euro
0 references
97,000.0 Euro
0 references
50.0 percent
0 references
1 January 2018
0 references
31 March 2021
0 references
FUNDACION CENTRO NAL DE INV. CARDIOVASCULARES CARLOS III
0 references
40°25'0.12"N, 3°42'12.89"W
0 references
28079
0 references
La enfermedad de Alzheimer (AD, por sus siglas en inglés) es la forma más común de demencia, afectando a 24 millones de personas en el mundo. Los enfoques actuales para tratar AD no han tenido éxito porque se han centrado en el momento del inicio de los síntomas, cuando la enfermedad es ya irreversible. El daño cerebral en AD comienza 20 años antes de que la demencia sea evidentes, lo que indica que el enfoque debería centrarse en las estrategias preventivas tempranas, por lo que es de suma importancia entender los factores que conducen al desarrollo de AD en su estadio asintomático. En los últimos años se ha relacionado AD con factores de riesgo de aterosclerosis. De hecho, similar a AD, la aterosclerosis comienza muchos años antes de que aparezcan los síntomas. Los estudios actuales que vinculan las dos patologías se basan en estudios transversales en estadios sintomáticos. Para entender la interrelación entre ambas enfermedades, proponemos llevar a cabo un estudio que evalúe las trayectorias (iniciación y progresión) de AD y aterosclerosis en sus estadios asintomáticos. Para ello aprovecharemos una gran cohorte de participantes asintomáticos de mediana edad en los cuales ya se ha caracterizado con detalle el grado de aterosclerosis subclínica, el estudio de progresión de la aterosclerosis temprana subclínica (PESA). Proponemos incluir en este estudio PESA distintos análisis cerebrales para detectar la disminución cognitiva sutil y los cambios cerebrales típicos de AD preclínico por imagen avanzada, y correlacionarlos con el grado y la progresión de la presencia de aterosclerosis subclínica. La demostración de trayectorias relacionadas de AD y aterosclerosis en sus estadios asintomáticos abrirá la posibilidad para futuras estrategias de intervención para frenar las epidemias globales de ambas enfermedades. (Spanish)
0 references
Alzheimer’s disease (AD) is the most common form of dementia, affecting 24 million people in the world. Current approaches to AD treatment have not been successful because they have focused on the time of onset of symptoms, when the disease is already irreversible. Brain damage in AD begins 20 years before dementia is evident, indicating that the focus should focus on early preventive strategies, so it is of utmost importance to understand the factors that lead to the development of AD in its asymptomatic stage. In recent years AD has been linked to risk factors for atherosclerosis. In fact, similar to AD, atherosclerosis begins many years before symptoms appear. Current studies linking the two pathologies are based on cross-sectional studies in symptomatic stages. To understand the interrelationship between the two diseases, we propose to carry out a study that evaluates the trajectories (initiation and progression) of AD and atherosclerosis in their asymptomatic stages. To do this, we will take advantage of a large cohort of asymptomatic middle-aged participants in whom the degree of subclinical atherosclerosis has already been characterised in detail, the study of progression of early subclinical atherosclerosis (PESA). We propose to include in this study PESA different brain analyses to detect subtle cognitive decline and brain changes typical of preclinical AD by advanced image, and correlate them with the degree and progression of the presence of subclinical atherosclerosis. The demonstration of related paths of AD and atherosclerosis in their asymptomatic stages will open up the possibility for future intervention strategies to curb the global epidemics of both diseases. (English)
12 October 2021
0 references
Madrid
0 references
Identifiers
PI17_00590
0 references